Dear Editor.

In a recent paper, Take *et al.* reported continued risk of gastric cancer after *Helicobacter pylori* (Hp) eradication when followed endoscopically up to 21.4 years.^[@bibr1-1756284820931717]^ The higher the degree of atrophy, the higher the yearly risk for gastric cancer.

After 30 years of search we still do not know the mechanism for Hp gastric carcinogenesis. However, Hp infection predisposes to gastric cancer only after having induced some degree of oxyntic atrophy.^[@bibr2-1756284820931717]^ We therefore proposed that hypergastrinemia secondary to hypoacidity caused Hp induced gastric cancer.^[@bibr3-1756284820931717]^

The increased frequency of gastric cancer in patients using proton pump inhibitors (PPIs) after Hp eradication^[@bibr4-1756284820931717]^ indicates an additive effect of Hp and PPI treatment *via* gastrin.^[@bibr5-1756284820931717]^ Profound inhibitors of acid secretion should accordingly not be given for the long-term in Hp positive patients and used with caution in previously Hp positive patients.

The proliferative effect of gastrin is concentration dependent without any threshold and maximal effect is reached at a lower concentration than mostly realized.^[@bibr6-1756284820931717],[@bibr7-1756284820931717]^ The gastrin immunoassays were introduced at a time without knowledge of Hp. Therefore, asymptomatic subjects with Hp infection were included among controls, making present upper normal levels too high.^[@bibr5-1756284820931717]^ It would have been of interest to know the gastrin values in the patients described by Take *et al.*^[@bibr1-1756284820931717]^ They also described that gastric cancers of diffuse type seemed to increase with time.^[@bibr1-1756284820931717]^ This cancer type we have described for more than 20 years to be of Enterochromaffin-like (ECL) cell origin,^[@bibr8-1756284820931717]^ the target cell of gastrin.

Finally, it should be recalled that we already have an efficient gastrin antagonist, netazepide, without side effects.^[@bibr9-1756284820931717]^
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